Edoxaban is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. The most common phase is Observational. The sponsor with the most trials is Nanjing First Hospital, Nanjing Medical University (1). The most-studied condition is Pulmonary Embolism.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
NCT06149533 · ClinicalTrials.gov ↗ · Thrombosis, Venous, Cancer, Catheter Complications
|
Phase 3 | Not yet open | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | China |
|
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
NCT07603700 · ClinicalTrials.gov ↗ · Pulmonary Embolism, Venous Thromboembolism
|
Observational | Not yet open | Nanjing First Hospital, Nanjing Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Nanjing First Hospital, Nanjing Medical University | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Edoxaban as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Nanjing First Hospital, Nanjing Medical University (1) and Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Edoxaban works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Edoxaban works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Edoxaban (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.